Showing results (21-30 of 299) with videos related to
Sort By:
Pageof 30
Clinical Lung Cancer|August 15, 2021
EGFR exon 20 Insertion NSCLC and Response to Platinum-Based ChemotherapyManan P Shah, Jacqueline V Aredo, Sukhmani K Padda, et al.Clinical Lung Cancer|February 19, 2019
Increased Galectin-1 Expression in Thymic Epithelial TumorsJonathan W Riess, Christina S Kong, Robert B West, et al.Lung Cancer (Amsterdam, Netherlands)|June 16, 2019
Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomesJacqueline V Aredo, Sukhmani K Padda, Christian A Kunder, et al.Cancer Treatment and Research Communications|April 29, 2026
KRAS G12C inhibitor outcomes in advanced non-small cell lung cancer by smoking history, performance status, and KEAP1 mutation statusZiheng Xu, Jacqueline V Aredo, Chloe C Su, et al.Cancer Chemotherapy and Pharmacology|November 13, 2021
A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancerSukhmani K Padda, Karen L Reckamp, Marianna Koczywas, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 18, 2014
Diffuse high intensity PD-L1 staining in thymic epithelial tumorsSukhmani K Padda, Jonathan W Riess, Erich J Schwartz, et al.Anti-Cancer Drugs|February 15, 2019
Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinibSamantha X Y Wang, Bing M Zhang, Heather A Wakelee, et al.Translational Lung Cancer Research|March 26, 2015
Adjuvant chemotherapy of completely resected early stage non-small cell lung cancer (NSCLC)Ying Liang, Heather A WakeleeJCO Precision Oncology|January 7, 2022
Computational Biological Modeling Identifies PD-(L)1 Immunotherapy Sensitivity Among Molecular Subgroups of KRAS-Mutated Non-Small-Cell Lung CancerSukhmani K Padda, Jacqueline V Aredo, Shireen Vali, et al.Pageof 30